2CL.F BridgeBio Pharma, Inc.

Healthcare Biotechnology Frankfurt Exchange
70.49 EUR
Close of Nov 12, 2026
53.30 77.81
Market cap
EUR 13.7B
P/E
-
P/B
127.53x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 2CL.F undervalued?

Graham number

The Graham number of BridgeBio Pharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BridgeBio Pharma, Inc. fundamental analysis

No fundamental analysis for BridgeBio Pharma, Inc. yet.

BridgeBio Pharma, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NU…

Full company profile